Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication CARDAMYST is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST is a calcium channel blocker indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults ( 1 ). FDA label
Also known as MSP-2017
Etripamil · 3 trials · 2 indications
The maximum reduction in ventricular rate, measured from ECG CMS recordings, within 30 minutes from first drug administration
Baseline ventricular rate is defined as the average heart rate over 5 minutes immediately prior to drug administration. Nadir is defined as the lowest moving average heart rate over 5 minutes recorded in the 60 minutes post drug administration.
The primary efficacy endpoint was the rate of successful PSVT conversion to sinus rhythm lasting at least 30 seconds within 15 minutes of study drug administration after a minimum of 5 minutes in sustained PSVT.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Patients will self-administer an initial dose of placebo for a perceived episode of AF with RVR, followed by an optional second dose 10 minutes later if symptoms persist. |
| Etripamil | EXPERIMENTAL | Patients will self-administer an initial dose of etripamil for a perceived episode of AF with RVR, followed by an optional second dose 10 minutes later if symptoms persist. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | The formulation of placebo will consist of water, sodium acetate, disodium EDTA, and sulfuric acid to reproduce the same pH as the etripamil formulation. |
| Etripamil | DRUG | The formulation of etripamil is for IN administration and will consist of etripamil, water, acetic acid, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid. The dose of etripamil to be evaluated in this study is 70 mg with an optional second dose of 70 mg 10 minutes after the first dose if symptoms persist. |
Inclusion Criteria: 1. Age 18 years and over. 2. Provision of written informed consent. 3. Documented history of symptomatic AF (paroxysmal, persistent, or permanent) with a ventricular rate of ≥110 bpm. * Documentation: electrocardiogram (ECG) tracing (including 12-lead ECG or ECG strip) showi...
Top 5 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | REGN | 3 | PHASE3 | REGN7508, REGN9933 |
| Johnson & Johnson | JNJ | 14 | PHASE3 | Milvexian |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Abelacimab, PKN605 |
| Milestone Pharmaceuticals, Inc. | MIST | 1 | PHASE3 | Etripamil |
| Bayer | BAYRY | 1 | PHASE2 | BAY 3670549 |
Etripamil is an investigational small molecule developed by Milestone Pharmaceuticals Inc. (ticker: MIST) for cardiovascular conditions. It is being studied in atrial fibrillation and paroxysmal supraventricular tachycardia (PSVT). Etripamil is currently in Phase 3 clinical development and is not approved for commercial use.
Etripamil is being developed to treat atrial fibrillation and paroxysmal supraventricular tachycardia (PSVT), two heart rhythm disorders. In PSVT, the goal is conversion of the arrhythmia to normal sinus rhythm. In atrial fibrillation, it is being evaluated in Phase 3 and earlier studies. It remains investigational.
Etripamil targets CAV1. CAV1 is a calcium channel, and Etripamil is a small molecule designed to act on this target. This mechanism underlies its development for cardiovascular rhythm conditions such as atrial fibrillation and paroxysmal supraventricular tachycardia (PSVT).
Etripamil is developed by Milestone Pharmaceuticals Inc., which trades under the ticker MIST. The company is advancing the drug as a nasal spray formulation, referenced as Etripamil Nasal Spray 70mg, across cardiovascular indications including atrial fibrillation and paroxysmal supraventricular tachycardia (PSVT).
Etripamil is in Phase 3 clinical development. It is investigational and has not been approved by the FDA. The Phase 3 program includes the ReVeRA-301 trial in atrial fibrillation, which is currently recruiting, while earlier Phase 2 studies in atrial fibrillation and PSVT have been completed.
Etripamil has been studied in three registered trials. NCT06716021 (ReVeRA-301) is a recruiting Phase 3 trial in atrial fibrillation with 750 participants across the United States, Canada, and the Netherlands. NCT04467905 (ReVeRA-201) was a completed Phase 2 atrial fibrillation trial, and NCT02296190 was a completed Phase 2 PSVT trial.